The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer
ASH 2024: Kura Oncology CEO Troy Wilson highlights combination data in 1L AML for the menin inhibitor ziftomenib
ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets
ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025
ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company
ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)
ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma
ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual Meeting
Janux's CEO David Campbell reviews this week's data from JANX007, the company's PSMA x CD3 masked bispecific for prostate cancer
Biotech CEO Sisterhood: Deborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into a position of leadership
BioVenture VoiCes Episode 7: MPM BioImpact's Ansbert Gadicke
The Co-Founder and CTO of Seoul based Organoid Sciences walks us through how the company is using organoids for regenerative medicine, CRO services, and precision medicine
The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring
Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines
BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans
Led by a longtime leader of Korea's biotech sector, GI Innovation has science-forward programs such as fusion proteins that aim to redefine IL-2 and an IgE trap that could go up against Xolair
Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies
.png){kind=logo}
